1. |
Gluz O, Liedtke C, Gottschalk N, et al. Triple-negative breast cancer-current status and future directions[J]. Ann Oncol, 2009, 20(12):1913-1927.
|
2. |
Medioni J, Huchon C, Le Frere-Belda MA, et al. Neoadjuvant dose-dense gemcitabine plus docetaxel and vinorelbine plus epiru-bicin for operable breast cancer:improved prognosis in triple-negative tumors[J]. Drugs RD, 2011, 11(2):147-157.
|
3. |
Liedtke C, Mazouni C, Hess KR, et al. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer[J]. J Clin Oncol, 2008, 26(8):1275-1281.
|
4. |
Hanley K, Wang J, Bourne P, et al. Lack of expression of andr-ogen receptor may play a critical role in transformation from in situ to invasive basal subtype of high-grade ductal carcinoma of the breast[J]. Hum Pathol, 2008, 39(3):386-392.
|
5. |
Pristauz G, Petru E, Stacher E, et al. Androgen receptor expression in breast cancer patients tested for BRCA1 and BRCA2 muta-tions[J]. Histopathology, 2010, 57(6):877-884.
|
6. |
Tang D, Xu S, Zhang Q, et al. The expression and clinical significance of the androgen receptor and E-cadherin in triple-negative breast cancer[J]. Med Oncol, 2012, 29(2):526-533.
|
7. |
Doane AS, Danso M, Lal P, et al. An estrogen receptor-negative breast cancer subset characterized by a hormonally regulated transcriptional program and response to androgen[J]. Oncogene, 2006, 25(28):3994-4008.
|
8. |
Agoff SN, Swanson PE, Linden H, et al. Androgen receptor expression in estrogen receptor-negative breast cancer. Immunohistochemical, clinical, and prognostic associations[J]. Am J Clin Pathol, 2003, 120(5):725-731.
|
9. |
Brattsand G. Correlation of oncoprotein 18/stathmin expression in human breast cancer with established prognostic factors[J]. Br J Cancer, 2000, 83(3):311-318.
|
10. |
Baquero MT, Hanna JA, Neumeister V, et al. Stathmin expression and its relationship to microtubule-associated protein tau and outcome in breast cancer[J]. Cancer, 2012, 118(19):4660-4669.
|
11. |
Rakha EA, Aleskandarany M, El-Sayed ME, et al. The prognosticsignificance of inflammation and medullary histological type ininvasive carcinoma of the breast[J]. Eur J Cancer, 2009, 45(10):.
|
12. |
Cao AY, He M, Liu ZB, et al. Outcome of pure mucinous breast carcinoma compared to infiltrating ductal carcinoma:a population-based study from China[J]. Ann Surg Oncol, 2012, 19(9):3019-3027.
|
13. |
Chen WY, Chen CS, Chen HC, et al. Mucinous cystadenocarcinoma of the breast coexisting with infiltrating ductal carcinoma[J]. Pathol Int, 2004, 54(10):781-786.
|
14. |
Shah C, Wilkinson JB, Shaitelman S, et al. Clinical outcomes using accelerated partial breast irradiation in patients with invasive lobular carcinoma[J]. Int J Radiat Oncol Biol Phys, 2011, 81(4):.
|
15. |
Fernández B, Paish EC, Green AR, et al. Lymph-node metastasesin invasive lobular carcinoma are different from those in ductal carcinoma of the breast[J]. J Clin Pathol, 2011, 64(11):995-1000.
|
16. |
Lerma E, Peiro G, Ramón T, et al. Immunohistochemical hetero-geneity of breast carcinomas negative for estrogen receptors,progesterone receptors and Her2/neu (basal-like breast carcinomas)[J]. Mod Pathol, 2007, 20(11):1200-1207.
|
17. |
Millikan RC, Newman B, Tse CK, et al. Epidemiology of basal-like breast cancer[J]. Breast Cancer Res Treat, 2008, 109(1):123-139.
|
18. |
Dent R, Trudeau M, Pritchard KI, et al. Triple-negative breast cancer:clinical features and patterns of recurrence[J]. Clin Cancer Res, 2007, 13(15 Pt 1):4429-4434.
|
19. |
Cimino-Mathews A, Hicks JL, Illei PB, et al. Androgen receptorexpression is usually maintained in initial surgically resected breast cancer metastases but is often lost in end-stage metastases found at autopsy[J]. Hum Pathol, 2012, 43(7):1003-1011.
|
20. |
Park S, Koo J, Park HS, et al. Expression of androgen receptorsin primary breast cancer[J]. Annals of oncology :official journal of the European Society for Medical Oncology / ESMO, 2010, 21(3):488-492.
|
21. |
Niemeier LA, Dabbs DJ, Beriwal S, et al. Androgen receptor in breast cancer:expression in estrogen receptor-positive tumors and in estrogen receptor-negative tumors with apocrine differentiation[J]. Mod Pathol, 2010, 23(2):205-212.
|
22. |
Qi JP, Yang YL, Zhu H, et al. Expression of the androgen receptorand its correlation with molecular subtypes in 980 Chinese breast cancer patients[J]. Breast Cancer (Auckl), 2012, 6:1-8.
|
23. |
Gonzalez-Angulo AM, Stemke-Hale K, Palla SL, et al. Androgenreceptor levels and association with PIK3CA mutations and prognosis in breast cancer[J]. Clin Cancer Res, 2009, 15(7):2472-2478.
|
24. |
Loibl S, Müller BM, von Minckwitz G, et al. Androgen receptorexpression in primary breast cancer and its predictive and prognostic value in patients treated with neoadjuvant chemotherapy[J]. Breast Cancer Res Treat, 2011, 130(2):477-487.
|
25. |
Holmfeldt P, Sellin ME, Gullberg M. Predominant regulators of tubulin monomer-polymer partitioning and their implication for cell polarization[J]. Life Sci, 2009, 66(20):3263-3276.
|
26. |
Singer S, Ehemann V, Brauckhoff A, et al. Protumorigenic overexpression of stathmin/Op18 by gain-of-function mutation in p53 in human hepatocarcinogenesis[J]. Hepatology, 2007, 46(3):759-768.
|
27. |
Alli E, Bash-Babula J, Yang JM, et al. Effect of stathmin on the sensitivity to antimicrotubule drugs in human breast cancer[J]. Cancer Res, 2002, 62(23):6864-6869.
|
28. |
Alli E, Yang JM, Ford JM, et al. Reversal of stathmin-mediated resistance to paclitaxel and vinblastine in human breast carcinoma cells[J]. Mol Pharmacol, 2007, 71(5):1233-1240.
|
29. |
Kavallaris M. Microtubules and resistance to tubulin-binding agents[J]. Nat Rev Cancer, 2010, 10(3):194-204.
|
30. |
-551.
|
31. |
-1787.
|